GlassScriptPhysician profile
Stephan Michael Carlson
NPI 1275680068
$184,045.90
in general payments reported to CMS, 2019-2025
11 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $16K · 2021: $26K · 2022: $26K · 2023: $30K · 2024: $23K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Consulting Fee: $7,617 · Food and Beverage: $3,614 · Travel and Lodging: $3,349 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,900.00 |
| Consulting Fee | $7,617.00 |
| Food and Beverage | $3,613.60 |
| Travel and Lodging | $3,349.13 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $102,219.44 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $70,862.40 | 2019-2025 | Aristada, Aristada Initio, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $9,792.81 | 2020-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $382.23 | 2020-2025 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $307.77 | 2019-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $234.84 | 2019-2025 | Ingrezza |
| Bioxcel Therapeutics, INC. | $70.48 | 2023-2024 | Igalmi |
| Abbvie INC. | $51.10 | 2024-2025 | |
| Lundbeck LLC | $43.77 | 2020-2024 | Abilify Maintena |
| Janssen Scientific Affairs, LLC | $41.23 | 2025 | Invega Sustenna |
| Indivior INC. | $39.83 | 2022-2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.